A Phase 1/2 Study of BA3071 in Patients With Solid Tumors

NCT05180799 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

320

Enrollment

INDUSTRY

Sponsor class

Conditions

NSCLC
Melanoma

Interventions

BIOLOGICAL: BA3071
BIOLOGICAL: Nivolumab
BIOLOGICAL: Pembrolizumab
DRUG: Pemetrexed (Alimta)

Sponsor

BioAtla, Inc.